Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors.

ESMO open·2026
Same author

Comparative study of safety and efficacy of closed dacryointubation vs. bicanalicular intubation in the treatment of upper tear duct obstruction in adult patients.

Journal francais d'ophtalmologie·2025
Same author

Improved activity and thermostability of glycosylating biocatalysts acting in neat natural deep eutectic solvents: Pushing boundaries of enzymes.

International journal of biological macromolecules·2025
Same author

Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project.

ESMO open·2025
Same author

Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.

Vaccine·2025
Same author

Cadmium availability in rhizosphere and non-rhizosphere soils in cacao farms in Santander, Colombia.

Environmental monitoring and assessment·2024

Related Experiment Video

Updated: Jul 5, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

MDX-RA Medarex Inc.

E Castillo1

  • 1Formulation Development, 6201 South Freeway, RI-26, Fort Worth, TX 76134-2099, USA. alconftw!rndmail2!castilloej@alconatt.attmail.com.

Idrugs : the Investigational Drugs Journal
|May 10, 2008
PubMed
Summary
This summary is machine-generated.

MDX-RA, an immunotoxin, shows promise in preventing secondary cataracts by targeting lens epithelial cells. Early trials indicate significantly reduced opacification compared to placebo, supporting its potential in cataract surgery patients.

More Related Videos

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
07:56

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts

Published on: January 29, 2018

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Experiment Videos

Last Updated: Jul 5, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
07:56

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts

Published on: January 29, 2018

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Secondary cataracts are a common complication following cataract surgery.
  • Current treatments for secondary cataracts are limited.
  • Medarex is developing MDX-RA, an immunotoxin, to prevent secondary cataracts.

Purpose of the Study:

  • To evaluate the efficacy and safety of MDX-RA in preventing secondary cataracts.
  • To assess the impact of MDX-RA on lens capsule opacification post-cataract surgery.

Main Methods:

  • MDX-RA, an immunotoxin comprising a murine monoclonal antibody (4197X) and ricin A chain toxin, is administered via intraocular injection.
  • Phase I/II and Phase III clinical trials are evaluating MDX-RA in patients undergoing cataract surgery.
  • Studies involve placebo controls and approximately 680 patients across multiple US sites.

Main Results:

  • Phase I/II trials demonstrated substantially less lens opacification in patients treated with MDX-RA compared to placebo.
  • Early results showed reduced lens capsule opacification in the MDX-RA group.
  • Further interim analyses are planned during the two-year follow-up period.

Conclusions:

  • MDX-RA shows potential as a novel therapeutic agent for preventing secondary cataracts.
  • The immunotoxin's targeted cytotoxic activity offers a promising approach to mitigate post-surgical complications.
  • Ongoing clinical trials will further define MDX-RA's role in ophthalmic therapeutics.